UHN Inpatient Hepatitis C & B Screening
Launched by JORDAN FELD · Nov 5, 2020
Trial Information
Current as of August 02, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to quickly test for Hepatitis C and Hepatitis B in patients admitted to the hospital. The goal is to see if using rapid screening methods—where patients can get results the same day—will help identify more cases of these viruses and get patients the care they need sooner. Currently, testing usually involves multiple visits and can take weeks to get results, which can delay treatment. By focusing on inpatient settings, this study aims to gather important information about how effective and acceptable this rapid testing approach is, especially among different age groups.
To participate in this trial, you need to be at least 18 years old and admitted to specific hospital units at Toronto General Hospital or Toronto Western Hospital. Unfortunately, patients who are expected to have less than six months to live, those unable to provide consent, or those with serious conditions that need urgent care won't be eligible. If you join the study, you can expect to undergo quick screening for these viruses and receive immediate support if you test positive, which could make a big difference in your health journey.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 years or older at time of consent
- • Patients admitted to GIMIUs at TGH or TWH
- Exclusion Criteria:
- • Patients whose end of life is expected to be less than 6 months
- • Patients who are unable or decline to provide informed consent
- • Patients with confirmed, active COVID-19 infections
- • Patients with immediate life-threatening conditions where screening for chronic HCV and HBV infection may delay urgent care
About Jordan Feld
Jordan Feld is a distinguished clinical trial sponsor known for its commitment to advancing medical research and innovation. With a focus on oncology and rare diseases, the organization collaborates with leading institutions and researchers to facilitate the development of novel therapies. Jordan Feld prioritizes patient safety and scientific integrity, ensuring that all trials adhere to rigorous regulatory standards. Through its strategic partnerships and dedication to excellence, the sponsor plays a pivotal role in bringing groundbreaking treatments to market, ultimately enhancing patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials